Grabar Law Office is investigating claims on behalf of shareholders of Replimune Group, Inc. (NASDAQ: REPL). The investigation concerns whether certain officers and directors breached the fiduciary duties they owed to the company.

Replimune Group, Inc. was founded in 2015 with the mission to transform cancer treatment by pioneering the development of novel oncolytic immunotherapies.

A recently filed federal securities fraud class action Complaint alleges that Replimune Group, Inc. (NASDAQ: REPL), through certain of its officers, made materially false or misleading statement regarding the Company’s IGNYTE trial, the purpose of which is to treat skin cancer. The Complaint alleges that Defendants made false and/or misleading statements and/or failed to disclose that: (1) Defendants recklessly overstated the IGNYTE trial’s prospects, given material issues that defendants knew or should have known of, which resulted in the FDA deeming the IGNYTE trial inadequate and not well-controlled; and (2) as a result, Defendants’ statements about Replimune’s business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all times.

WHAT YOU CAN DO NOW: If you purchased Replimune Group, Inc. (NASDAQ: REPL) shares prior to November 22, 2024, and still hold shares today, you are encouraged to contact Joshua Grabar at jgrabar@grabarlaw.com, or call 267-507-6085.  You can seek corporate reforms, the return of funds back to the company, and a court approved incentive award at no cost to you whatsoever.  If, alternatively, you purchased your shares between November 22, 2024, and July 21, 2025, you can participate in the class action.